Stockscreener 앱 받기
2.1274
2.14%
0.0274
전일 마감가:
$2.10
열려 있는:
$2.1
하루 거래량:
2,067
Relative Volume:
0.03
시가총액:
$103.00M
수익:
-
순이익/손실:
$-9.51M
주가수익비율:
-8.5096
EPS:
-0.25
순현금흐름:
$-10.96M
1주 성능:
+10.00%
1개월 성능:
-9.87%
6개월 성능:
+53.21%
1년 성능:
+30.00%
1일 변동 폭
$2.10
$2.1841
1주일 범위
$2.03
$2.1858
52주 변동 폭
$1.12
$2.55
Medicinova Inc Stock (MNOV) Company Profile
명칭
Medicinova Inc
전화
858-373-1500
주소
4275 EXECUTIVE SQUARE, LA JOLLA, CA
MNOV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
2.18 | 103.00M | 0 | -9.51M | -10.96M | -0.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.59 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
721.42 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
622.80 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.20 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.57 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-10 | 개시 | Maxim Group | Buy |
| 2019-03-25 | 재개 | B. Riley FBR | Buy |
| 2018-03-28 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-04-18 | 개시 | Credit Suisse | Outperform |
| 2013-01-04 | 재확인 | Ladenburg Thalmann | Buy |
| 2012-05-24 | 다운그레이드 | MLV & Co | Buy → Hold |
| 2011-10-18 | 재확인 | MLV Capital | Buy |
| 2011-06-22 | 개시 | Global Hunter Securities | Buy |
| 2010-05-12 | 개시 | Wedbush | Outperform |
| 2008-11-12 | 재확인 | Ladenburg Thalmann | Buy |
| 2008-05-15 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-07-09 | 개시 | Punk, Ziegel & Co | Buy |
모두보기
Medicinova Inc 주식(MNOV)의 최신 뉴스
MediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving AverageTime to Sell? - MarketBeat
StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV) - MarketBeat
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com - Defense World
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV) - MarketBeat
MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com - Defense World
MediciNova (NASDAQ:MNOV) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial… - MSN
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial - Smartkarma
MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com - Defense World
Drug Trial Shows Positive Interim Results for ALS Treatment - Streetwise Reports
MediciNova Presents Study Update and Interim Analysis of - GlobeNewswire
MediciNova Reports Strong Interim Data from ALS Drug Trial, Shows Promising Correlations - StockTitan
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at D. Boral Capital - Defense World
MediciNova stock undervalued? D. Boral sees upside in ALS & MS market opportunities - Investing.com India
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Zacks sees 400% upside for MediciNova amid incoming damages from Sanofi/Novartis dispute - Kursiv Media
MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement - Smartkarma
MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement… - MSN
MediciNova, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MediciNova reports progress in ALS and Long COVID trials - Investing.com
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders - GlobeNewswire
MediciNova Partners with NIH for ALS Trial, Reports $42.3M Cash Position | MNOV Stock News - StockTitan
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver - The Manila Times
MediciNova Receives Notice of Allowance from United States - GlobeNewswire
MediciNova Secures Key Patent for Diabetes Treatment MN-001 Through 2042 | MNOV Stock News - StockTitan
MediciNova stock hits 52-week high at $2.17 amid growth - Investing.com India
MediciNova: Q3 Earnings Snapshot - Darien Times
3 US Penny Stocks With Market Caps Over $40M To Consider - Simply Wall St
MediciNova stock hits 52-week high at $2.17 amid growth By Investing.com - Investing.com UK
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis - The Manila Times
MediciNova Secures Major Settlement from Sanofi-Novartis Litigation, Boosts Clinical Pipeline | MNOV Stock News - StockTitan
Idiopathic Pulmonary Fibrosis Management Market Share and Size Report 2024-2031 - InsightAce Analytic
MediciNova (NASDAQ:MNOV shareholders incur further losses as stock declines 11% this week, taking five-year losses to 80% - Simply Wall St
MediciNova (NASDAQ:MNOV) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Medicinova Inc (MNOV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.29%
0.19%
자본화:
|
볼륨(24시간):